After 20 years of intensive research and development activity in the field of haematology and oncology, medac received EU-wide marketing authorisation for its new product Trecondi^® (treosulfan) on 20 June 2019. medac‘s haematology portfolio is strengthened once again with this innovative therapeutic agent.

Trecondi^® is the first and only product containing treosulfan to have received marketing authorisation in Germany in haematology and therefore offers a new perspective compared with previous therapies.

medac will begin the official sale of Trecondi^® in Germany in August.